QDEL vs TMO
QDEL: Global diagnostics company providing immunoassay, molecular testing, clinical chemistry, and transfusion medicine solutions across labs, point-of-care, and molecular platforms. TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries.
Side-by-side fundamentals
| Metric | QDEL | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $16.58 | $572.32 | |
| Market cap as of 2026-07-24 | $1.1B | $214.1B | |
| P/E as of 2026-07-24 | n/a | 31.28 | |
| PEG as of 2026-07-24 | -0.00 | 2.89 | QDEL lower |
| Net margin as of 2026-07-24 | -45.6% | +15.2% | TMO higher |
| Gross margin as of 2026-07-24 | +45.0% | +40.9% | QDEL higher |
| Operating margin as of 2026-07-24 | -37.2% | +17.5% | TMO higher |
| ROE as of 2026-07-24 | -56.3% | +13.2% | TMO higher |
| ROA as of 2026-07-24 | -20.6% | +6.4% | TMO higher |
| Debt / equity as of 2026-07-24 | 1.45 | 0.83 | TMO lower |
| Revenue growth (YoY) as of 2026-07-24 | -3.9% | +5.4% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | -0.3% | QDEL higher |
| Dividend yield as of 2026-07-24 | n/a | +0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 0.69 | 0.84 | |
| 1-year return as of 2026-07-23 close | -37.7% | +22.6% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.